EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) recently announced its participation in two upcoming conferences. The BTIG Biotechnology Conference is scheduled for August 9, 2022, at 10:00 a.m. ET, featuring a panel discussion. Additionally, the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference will take place on August 17, 2022, with corporate presentations at 7:00 a.m. ET and 11:00 a.m. ET. Webcasts of both events will be available on the company's website, with replays accessible for 90 days.

WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ will present at the following upcoming conferences:

• BTIG Biotechnology Conference
  

Forum: Panel
Date: Tuesday, August 9, 2022
Time: 10:00 a.m. ET

• H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
  

Forum: Corporate Presentation / Panel
Date: Wednesday, August 17, 2022
Time: 7:00 a.m. ET / 11:00 a.m. ET

A webcast and subsequent archived replay of the H.C. Wainwright 2^nd Annual Ophthalmology Virtual Conference corporate presentation and panel may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. The live webcast of the BTIG panel will be available on BTIG’s conference website at the time of the event, and a replay will be available through BTIG’s research access.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What conferences will EyePoint Pharmaceuticals present at in August 2022?

EyePoint Pharmaceuticals will present at the BTIG Biotechnology Conference on August 9 and the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022.

When is the BTIG Biotechnology Conference presentation for EyePoint Pharmaceuticals?

The BTIG Biotechnology Conference presentation is set for August 9, 2022, at 10:00 a.m. ET.

What time will the H.C. Wainwright conference presentations occur for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals will present at the H.C. Wainwright conference on August 17, 2022, at 7:00 a.m. ET and 11:00 a.m. ET.

Where can I watch the EyePoint Pharmaceuticals conference presentations?

The presentations can be accessed via the Investors section of EyePoint Pharmaceuticals' website, with replays available for 90 days.